Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New Term Proposed for Infiltrates of Distinct mDCs

Ann Diagn Pathol; 2016 Dec; Margo, Momtahen, et al

Publish date:

Investigators proposed the term “cutaneous mDC cell dyscrasia” for distinctive infiltrates of differentiated mDCs reflective of underlying myeloproliferative disease after conducting an analysis of 11 individuals.

Researchers performed routine hematoxylin and eosin stain, followed by selective phenotypic studies. Among the results:

  • The biopsies verified a dermal-based monomorphic small mononuclear cell infiltrate.
  • The cells expressed CD14, CD11c, HLA-DR, as well as granzyme and lysozyme that defines terminally differentiated monocyte/dendritic cells.
  • Expression of BDCA-3 (CD141) by the tumor cells showed that they were myeloid dendritic cells.
  • Each patient had a prior or subsequent diagnosis of an abnormal bone marrow biopsy that included myelodysplastic syndrome, myelofibrosis, chronic myelomonocytic leukemia, and acute myelogenous leukemia.

Citation:

Margo C, Momtahen S, Verma S, et al. Cutaneous myeloid dendritic cell dyscrasia: A cutaneous clonal monocytosis associated with chronic myeloproliferative disorders and peripheral blood monocytosis. Ann Diagn Pathol. 2016;12:85-91. doi:10.1016/j.anndiagpath.2016.08.001.

This Week's Must Reads